3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Stomach Neoplasms
12
Colorectal Neoplasms
10
Adenocarcinoma
6
Breast Neoplasms
5
Pancreatic Neoplasms
4
Neoplasm Metastasis
4
Esophageal Neoplasms
4
Sarcoma
2
Salivary Gland Neoplasms
2
Prostatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasms
2
Melanoma
2
HER2-positive Gastric Cancer
2
Gastrointestinal Neoplasms
2
Endometrial Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Renal Cell
2
Adenocarcinoma Of Esophagus
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Thyroid Neoplasms
1
Testicular Neoplasms
1
Small Cell Lung Carcinoma
1
Rectal Neoplasms
1
Neoplasm, Residual
1
Mouth Neoplasms
1
Interventions
fludarabine
3
Vaccines
3
Radiotherapy
3
Papillomavirus Vaccines
3
Nivolumab
3
Cyclophosphamide
3
pembrolizumab
2
entinostat
2
aldesleukin
2
aflibercept
2
Trastuzumab
2
Surveys and Questionnaires
2
Specimen Handling
2
Radiation
2
Observation
2
Magnetic Resonance Spectroscopy
2
Ipilimumab
2
CTLA-4 Antigen
2
Adoptive Transfer
2
trastuzumab deruxtecan
1
tivozanib
1
tipifarnib
1
rocakinogene sifuplasmid
1
oncogene protein E7, Human papillomavirus type 16
1
nanocis
1
durvalumab
1
bintrafusp alfa protein, human
1
atezolizumab
1
Watchful Waiting
1
Vorinostat
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Vulvar Neoplasms
×
trastuzumab deruxtecan
×
Gastrointestinal
×
Clear all
NCT07124000
2026-06-01
DP-04
AstraZeneca
Recruiting
100 enrolled